Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
VOR
SellHot AirVor Biopharma Inc. · Healthcare · United States · $1.3B · Avg Vol: $17M/d
COMPANY DESCRIPTION
Vor Biopharma is a clinical-stage biotechnology company developing engineered hematopoietic stem cell (eHSC) therapies for blood cancers. Its proprietary eHSC platform aims to enable targeted therapies post-transplant, addressing a significant unmet medical need. This focus on immuno-oncology and cell therapy offers a potential competitive advantage in a rapidly evolving treatment landscape.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — |
| EPS | -2.84 | -2.19 | -3.92 | -70.50 | — | 180.58 |
| Shares | 54.2M | 54.2M | 54.2M | 38.7M | -28.5% | — |
| Debt | 38.9M | 35.7M | 31.8M | 3.0M | -57.4% | 2.9M |
| Equity | 250.6M | 150.7M | 96.7M | -164.3M | -37.9% | — |
| Op CF | -85.1M | -100.3M | -99.7M | -142.7M | — | -140.1M |
| Inv CF | -94.1M | 71.0M | 96.9M | -48.8M | — | — |
| Fin CF | 117.1M | 2.9M | 53.4M | 503.8M | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VOR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| VOR | Vor Biopharma Inc.(you) | $1.3B | 20 | Sell |
| ORIC | ORIC Pharmaceuticals, Inc. | $1.4B | 22 | Sell |
| REPL | Replimune Group, Inc. | $1.5B | 19 | Strong Sell |
| AVBP | ArriVent BioPharma, Inc. | $1.5B | 22 | Sell |
| JBIO | Jade Biosciences, Inc. | $1.3B | 24 | Sell |
| CGEM | Cullinan Therapeutics, Inc. | $1.3B | 26 | Sell |
| MNKD | MannKind Corporation | $1.3B | 25 | Sell |
| ABSI | Absci Corporation | $1.5B | 17 | Strong Sell |
| KURA | Kura Oncology, Inc. | $1.1B | 23 | Sell |
| DMRA | Damora Therapeutics, Inc. | $1.8B | 20 | Sell |
Peer medians: ROE -30.7% · P/E 27.1x · Gross margin 58.3%